Ceftobiprole: Farewell or just a delay?
Chahine
Elias B
EB
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D002511:Cephalosporins / Q000627:therapeutic use*; D017277:Drug Approval; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D014481:United States; D014486:United States Food and Drug Administration; D014640:Vancomycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C443755:ceftobiprole; D014640:Vancomycin